Niagen Bioscience Inc. (NAGE)
NAGE trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/0001386570-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NAGE on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001386570 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $129.4M |
| Net income | $17.4M |
| Operating income | $16.3M |
| Net margin | 13.4% |
| Operating margin | 12.6% |
| Revenue growth | +29.9% |
| Cash | $64.8M |
| Total assets | $106.4M |
| P/E (computed) | 9.2× |
| P/S (computed) | 1.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $69.5M cash; operating cash flow $1.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 79,196,903 (2026-10-30); 79,806,139 a year earlier; 75,124,418 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-07-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Crowe LLP, Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2024-12-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $46K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $27.2M | -$1.2M | $2.6M | $69.5M | No debt tags | $122.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $29.8M | $963K | $2.8M | $66.7M | No debt tags | $129.1M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $31.5M | $6.3M | -$1.2M | $66.5M | No debt tags | $130.4M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $33.8M | $4.1M | $679K | $64.8M | No debt tags | $129.4M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $34.0M | $4.6M | $3.7M | $64.1M | No debt tags | $124.7M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $31.1M | $3.6M | $1.3M | $60.3M | No debt tags | $116.3M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $30.5M | $5.1M | $7.9M | $55.5M | No debt tags | $107.9M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $29.1M | $7.2M | $8.6M | $44.5M | No debt tags | $99.6M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-07-10 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 981 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | -19.8% |
| 3 months | -32.1% |
| Year to date | -67.5% |
| 1 year | -70.4% |
| From 52-week high | -70.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
| CGC | Canopy Growth Corporation Common Shares | $0.5460 | -2.71% | $231.2M |
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier